We acknowledge our partners and funders in the preparation of this publication. The American Society of Tropical Medicine and Hygiene has waived the open access fee for this article due to the ongoing COVID-19 pandemic.
Rayner CR et al., 2020. Accelerating clinical evaluation of repurposed combination therapies for COVID-19. Am J Trop Med Hyg 103: 1364.
Sukhatme VP , Reiersen AM , Vayttaden SJ , Sukhatme VV , 2021. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol 652: 652688.
Reis G et al., 2022. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 10: e42–e51.
Lenze EJ , Mattar C , Zorumski CF , Stevens A , Schweiger J , Nicol GE , Miller JP , Yang L , Yingling M , Avidan MS , 2020. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 324: 2292–2300.
Seftel D , Boulware DR , 2021. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis 8: ofab050.
Rae M , Claxton G , Kurani N , McDermott D , Cox C , 2020. Potential Costs of Coronavirus Treatment for People with Employer AU8 Coverage. Peterson–Kaiser Family Foundation Heath System Tracker. Available at: https://www.healthsystemtracker.org/brief/potential-costs-of-coronavirus-treatment-for-people-with-employer-coverage/. Accessed August 23, 2022.
Drummond MF , Sculpher MJ , Claxton K , Stoddart GL , Torrance GW , 2015. Methods for the Economic Evaluation of Health Care Programmes. Oxford, United Kingdom: Oxford University Press.
Briggs A , Sculpher M , Claxton K , 2006. Decision Modelling for Health Economic Evaluation. Oxford, United Kingdom: Oxford University Press.
Calusic M , Marcec R , Luksa L , Jurkovic I , Kovac N , Mihaljevic S , Likic R , 2022. Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol 88: 2065–2073.
Goswami H , Alsumali A , Jiang Y , Schindler M , Duke ED , Cohen J , Briggs A , Puenpatom A , 2022. Cost-effectiveness analysis of molnupiravir versus best supportive care for the treatment of outpatient COVID-19 in adults in the US. PharmacoEconomics 40: 699–714.
Official Data Foundation Medical care price inflation, 2012→2021. Available at: https://www.in2013dollars.com/Medical-care/price-inflation. Accessed August 23, 2022.
Bartsch SM , Ferguson MC , McKinnell JA , O’Shea KJ , Wedlock PT , Siegmund SS , Lee BY , 2020. The potential health care costs and resource use associated with COVID-19 In the United States: a simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States. Health Aff (Millwood) 39: 927–935.
- Search Google Scholar
- Export Citation
Bartsch SM Ferguson MC McKinnell JA O’Shea KJ Wedlock PT Siegmund SS Lee BY 2020. The potential health care costs and resource use associated with COVID-19 In the United States: a simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States. Health Aff (Millwood) 39: 927– 935.
Husereau D et al., 2013. Consolidated health economic evaluation reporting standards (CHEERS) statement. Int J Technol Assess Health Care 29: 117–122.
Lee TC , Vigod S , Bortolussi-Courval É , Hanula R , Boulware DR , Lenze EJ , Reiersen AM , McDonald EG , 2022. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. JAMA Netw Open 5: e226269–e226269.
Minnesota Department of Health COVID-19 Vaccine Breakthrough Data. COVID-19 Situation Update. Available at: https://www.health.state.mn.us/diseases/coronavirus/stats/vbt.html. Accessed August 23, 2022.
Ohsfeldt RL , Choong CK-C , Mc Collam PL , Abedtash H , Kelton KA , Burge R , 2021. Inpatient hospital costs for COVID-19 patients in the United States. Adv Ther 38: 5557–5595.